Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Clin Exp Allergy. 2019 Sep 30;50(1):5–14. doi: 10.1111/cea.13491

Figure 4.

Figure 4.

Potential sites of action of Dupilumab in inhibiting allergic inflammation. Dupilumab can act to inhibit TH2 cell differentiation, the transformation of Treg cells into ex-Treg cells in the context of allergic inflammation, and IgE production by B cells, driven by T follicular helper (TFH)- derived IL-4. It can also prevent IL-4-related vascular endothelium dysfunction. Furthermore, it can inhibit ILC2 induction via eosinophils and basophils.